GtoPdb Ligand ID: 6852

Synonyms: MK-0683 | MK0683 | SAHA | suberoylanilide hydroxamic acid | Zolinza®
vorinostat is an approved drug (FDA (2006))
Compound class: Synthetic organic
Comment: Vorinostat inhibits Class I, II and IV histone deacetylases (our pages for HDACs are available using this link).
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: vorinostat

2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 78.43
Molecular weight 264.15
XLogP 1.85
No. Lipinski's rules broken 0
Canonical SMILES ONC(=O)CCCCCCC(=O)Nc1ccccc1
Isomeric SMILES ONC(=O)CCCCCCC(=O)Nc1ccccc1
InChI InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
No information available.
Summary of Clinical Use
Used in cutaneous T-cell lymphoma to treat cutaneous manifestations in patients with progressive, persistent or recurrent disease.
Mechanism Of Action and Pharmacodynamic Effects
It is postulated that the antineoplastic activity of this compound arises from its inhibition of histone deacetylases, causing an accumulation of acetylated histones and thereby inducing cell cycle arrest and/or apoptosis of some transformed cells.
External links